PHEBURANE by is a Prescription medication manufactured, distributed, or labeled by Medunik USA. Drug facts, warnings, and ingredients follow.
PHEBURANE is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). (1)
Limitations of Use
PHEBURANE is not indicated for the treatment of acute hyperammonemia. (1)
Oral pellets: 84 g of sodium phenylbutyrate per bottle. (3)
None. (4)
Most common adverse reactions (incidence ≥ 3%) are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Medunik USA, Inc. at 1-844-884-5520 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 8/2023
PHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS).
Limitations of Use
Episodes of acute hyperammonemia may occur in patients while on PHEBURANE. PHEBURANE is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels.
PHEBURANE treatment should be supervised by a healthcare provider experienced in the treatment of urea cycle disorders.
The recommended dosage of PHEBURANE (measured as sodium phenylbutyrate) for patients with urea cycle disorders is:
The maximum dosage is 20 grams per day. Combine PHEBURANE with dietary protein restriction and, in some cases, amino acid supplementation (e.g., essential amino acids, arginine, citrulline, and protein-free calorie supplements).
Measure the dose using only the calibrated spoon provided in the packaging. This calibrated dosing spoon directly measures PHEBURANE oral pellets as sodium phenylbutyrate [see Dosage and Administration (2.4)].
If a dose is missed, take the missed dose as soon as possible. There should be at least 3 hours between two doses and doses should not be doubled to make up for the missed dose.
Monitor plasma ammonia levels to determine the need for dosage adjustment. Adjust the PHEBURANE dosage to maintain the plasma ammonia level within the normal range for the patient’s age, taking into consideration their clinical condition (e.g., nutritional requirements, protein intake, growth parameters, etc.).
Monitor patients for potential neurotoxicity and obtain measurements of plasma phenylacetate and phenylacetylglutamine levels [see Warnings and Precautions (5.1), Adverse Reactions (6)]. If neurologic symptoms (e.g. vomiting, nausea, headache, somnolence or confusion) are present in the absence of high ammonia levels or other intercurrent illnesses, consider reducing the dose of PHEBURANE.
For patients with hepatic impairment, start at the lower end of the recommended dosing range and maintain patients on the lowest dose necessary to control plasma ammonia levels [see Use in Specific Populations (8.7)].
For oral administration only. Administration via gastrostomy or nasogastric tubes has not been evaluated.
Administration of PHEBURANE oral pellets with other foods has not been studied and is not recommended. Additionally, administration with soft food is only recommended in patients old enough to consume soft foods.
Increased exposure to phenylacetate, the major metabolite of PHEBURANE, may be associated with neurotoxicity in patients with UCDs. In a study of adult cancer patients receiving intravenous phenylacetate, 250-300 mg/kg/day for 14 days, repeated at 4-week intervals, signs and symptoms of neurotoxicity, which were reversible upon discontinuation, were seen at plasma concentrations ≥ 3.5 mmol/L, and included somnolence, fatigue, and light headedness [see Adverse Reactions (6)]. PHEBURANE is not approved for intravenous use or for treatment of patients with cancer.
If symptoms of vomiting, nausea, headache, somnolence or confusion are present in the absence of high ammonia levels or other intercurrent illnesses, consider reducing the dose of PHEBURANE [see Dosage and Administration (2.2)].
Phenylacetate caused neurotoxicity when given subcutaneously in rat pups [see Use in Specific Populations (8.4)].
Renal excretion of phenylacetylglutamine may induce urinary loss of potassium. Monitor serum potassium during therapy and initiate appropriate treatment when necessary.
PHEBURANE contains 124 mg (5.4 mmol) of sodium per gram of sodium phenylbutyrate, corresponding to 2.5 g (108 mmol) of sodium in the maximum daily dose of 20 g of sodium phenylbutyrate. In order to decide if administration of PHEBURANE is appropriate in patients with diseases that involve edema such as heart failure, cirrhosis, or nephrosis, calculate the total amount of sodium patients will be exposed to based on their weight or body surface area (BSA) [see Dosage and Administration (2.1)]. If a patient develops new-onset edema or worsening edema while on treatment, discontinue administration of PHEBURANE and initiate appropriate therapy.
PHEBURANE contains 768 mg of sucrose per gram of sodium phenylbutyrate, corresponding to 15.4 g of sucrose in the maximum daily dose of 20 g of sodium phenylbutyrate. This should be considered in patients with diabetes mellitus. Avoid use of PHEBURANE in patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
The following adverse reactions associated with the use of sodium phenylbutyrate were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Most common adverse reactions (incidence ≥ 3%) are amenorrhea or menstrual dysfunction (irregular menstrual cycles), decreased appetite, body odor and bad taste or taste aversion.
Less Common Clinical Adverse Reactions
Blood and lymphatic system disorders: aplastic anemia, ecchymoses
Cardiac disorders: arrhythmia
Gastrointestinal disorders: abdominal pain, decreased appetite, gastritis, nausea and vomiting, constipation, rectal bleeding, peptic ulcer disease, pancreatitis
Metabolism and nutrition disorders: increased weight, edema
Nervous system disorders: syncope, headache
Psychiatric disorders: depression
Renal and urinary disorders: renal tubular acidosis
Skin and subcutaneous tissue disorders: rash
Laboratory Adverse Reactions
Blood and lymphatic system disorders: anemia, leukopenia and leukocytosis, thrombocytopenia, thrombocytosis
Hepatobiliary disorders: hyperbilirubinemia, increased blood alkaline phosphatase, increased transaminases
Metabolism and nutrition disorders: acidosis, alkalosis, hyperchloraemia, hypophosphataemia, hyperuricemia, hyperphosphatemia, hypernatremia, hypokalemia, hypoalbuminemia, decreased total protein
Clinical Adverse Reactions with Use of Phenylacetate
Nervous system disorders: Neurotoxicity was reported in cancer patients receiving intravenous phenylacetate, the major metabolite of PHEBURANE (PHEBURANE is not approved for intravenous use or for treatment of patients with cancer). Signs and symptoms were predominately somnolence, fatigue, and dizziness (lightheadedness); less frequently reported were headache, dysgeusia, hypoacusis, disorientation, memory impairment, and exacerbation of a pre-existing neuropathy.
Corticosteroids
Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels.
Valproic Acid and Haloperidol
Hyperammonemia may be induced by haloperidol and by valproic acid.
Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE.
Probenecid
Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when probenecid is used concomitantly with PHEBURANE [see Dosage and Administration (2.2)].
Risk Summary
Available data with sodium phenylbutyrate use in pregnant women are insufficient to identify a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with sodium phenylbutyrate. Based on published animal data, phenylacetate may be neurotoxic to the developing brain (see Data).
There are serious risks to the mother and fetus associated with untreated urea cycle disorders during pregnancy which can result in serious morbidity and mortality to the mother and fetus (see Clinical Considerations).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Disease-Associated Maternal and/or Embryo/Fetal Risk
Pregnancy is a time of increased metabolic demand which increases the risk for hyperammonemic episodes when metabolic demands are not met. Hyperammonemic episodes in pregnancy are associated with impaired cognition in the mother and an increased risk of maternal and fetal death.
In rats, intrauterine exposure to phenylacetate produced lesions in the neonatal brain in layer 5 of the cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.
Risk Summary
There are no data on the presence of sodium phenylbutyrate and its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PHEBURANE and any potential adverse effects on the breastfed infant from PHEBURANE or from the underlying maternal condition.
The safety and effectiveness of PHEBURANE have been established as adjunctive therapy to the standard of care, which includes dietary management, in the chronic management of pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS).
PHEBURANE is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels.
The sodium content of PHEBURANE has the potential to cause new-onset edema or worsening edema from salt and water retention, particularly in patients with underlying predisposing conditions [see Warnings and Precautions (5.3)].
Neurotoxicity has been observed in juvenile animals with phenylacetate exposure [see Warnings and Precautions (5.1)].
Juvenile Animal Toxicity Data
When given subcutaneously to rat pups, 190–474 mg/kg phenylacetate caused decreased proliferation and increased loss of neurons, and it reduced CNS myelin. Cerebral synapse maturation was retarded, and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth.
Clinical studies of PHEBURANE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
No studies with PHEBURANE were conducted in subjects with renal impairment. Monitor plasma ammonia levels when starting patients with impaired renal function on PHEBURANE [see Clinical Pharmacology (12)].
No studies with PHEBURANE were conducted in subjects with hepatic impairment. Start at the lower end of the recommended dosing range and maintain patients with hepatic impairment on the lowest dose necessary to control plasma ammonia levels [see Clinical Pharmacology (12.3), Dosage and Administration (2.3)].
Overdoses of PHEBURANE exceeding ten-fold the maximum recommended dosage may produce emesis, CNS depression, metabolic acidosis with or without respiratory alkalosis, hypernatremia, hypokalemia, and hypophosphatemia. Symptoms of overdose overlap with those of acute hyperammonemia. If overdose occurs, discontinue PHEBURANE, monitor plasma phenylacetate and ammonia levels closely, and institute appropriate emergency management, which may include hemodialysis, continuous veno-venous hemofiltration (CVVH) or extracorporeal membrane oxygenation (ECMO).
PHEBURANE (sodium phenylbutyrate) oral pellets is a nitrogen binding agent. Sodium phenylbutyrate is a white or yellowish-white powder, freely soluble in water and in methanol, and practically insoluble in methylene chloride. It is known chemically as sodium 4-phenylbutanoate with a molecular weight of 186.19 and the molecular formula C10H11NaO2.
Structural formula:
Each bottle of PHEBURANE contains 84 g of sodium phenylbutyrate (equivalent to 74 g of phenylbutyrate) in 174 g of oral pellets. Each gram of pellets contains 483 mg of sodium phenylbutyrate (equivalent to 423 mg of phenylbutyrate). PHEBURANE contains the following inactive ingredients: ethylcellulose, hypromellose, polyethylene glycol 1500, povidone K25, and sugar spheres.
Sodium phenylbutyrate is a pro-drug and is metabolized to phenylacetate. Phenylacetate is a metabolically-active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
In patients with urea cycle disorders, sodium phenylbutyrate decreased elevated plasma ammonia and glutamine levels.
The pharmacokinetics of phenylbutyrate and its metabolite phenylacetate were characterized in healthy adult subjects following a single oral administration of PHEBURANE (3 g of sodium phenylbutyrate) under fasted and fed conditions.
Absorption
Under fasted condition, the mean (SD) maximum plasma concentration (Cmax) of phenylbutyrate ranged from 146 (30) to 169 (33) μg/mL, which was achieved at approximately 0.6 hour after PHEBURANE administration. The mean (SD) area under the plasma concentration-time curve (AUC) of phenylbutyrate ranged from 272 (78) to 283 (68) h*μg/mL.
Effect of Food
Compared to fasted condition, AUC of phenylbutyrate decreased by 40-45% and Cmax of phenylbutyrate decreased by 55%, when PHEBURANE was administered with a high-fat, high-calorie meal (total 800 to 1000 calories with approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively). When PHEBURANE was administered with a normal-fat, normal-calorie, low-protein meal (total 600 to 700 calories with approximately 60, 200, and 400 calories from protein, fat, and carbohydrate, respectively), AUC of phenylbutyrate decreased by 56-63% and Cmax decreased by 43-45% compared to fasted condition.
Elimination
The mean half-life of phenylbutyrate ranged from 0.5 to 0.8 hour.
Metabolism
Following oral administration, sodium phenylbutyrate is metabolized by β-oxidation into phenylacetate, which is converted to its coenzyme A ester, phenylacetyl-coenzyme A and further conjugated with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys. The major sites for metabolism of sodium phenylbutyrate are the liver and kidneys. Phenylacetate is also hydrolysed by esterases in liver and blood.
Excretion
Approximately 80–100% of sodium phenylbutyrate is excreted by the kidneys within 24 hours as phenylacetylglutamine. For each gram of sodium phenylbutyrate administered, it is estimated that between 0.12–0.15 grams of phenylacetylglutamine nitrogen are produced.
Specific Populations
Patients with Renal Impairment or Hepatic Impairment
PHEBURANE has not been studied in patients with renal impairment or in patients with hepatic impairment.
Drug Interaction Studies
In vitro or clinical studies with PHEBURANE for determination of potential drug-drug interaction have not been conducted.
PHEBURANE (sodium phenylbutyrate) oral pellets consists of white to off-white pellets and is available in a child-resistant high-density polyethylene (HDPE) bottle with a desiccant in the cap.
Each bottle contains 84 g of sodium phenylbutyrate (equivalent to 74 g of phenylbutyrate) in 174 g of oral pellets (NDC: 71770-200-10). Each gram of pellets contains 483 mg of sodium phenylbutyrate (equivalent to 423 mg of phenylbutyrate).
A calibrated measuring spoon that dispenses up to 3 g of sodium phenylbutyrate in increments of 0.25 g is provided in the packaging.
Store PHEBURANE at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
Discard any remaining PHEBURANE 45 days after first opening of the bottle.
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Neurotoxicity
Advise the patient or caregiver that neurotoxicity may occur during PHEBURANE treatment. Inform the patient or caregiver of the signs and symptoms of this risk and to contact the healthcare provider immediately if signs and symptoms occur [see Warnings and Precautions (5.1)].
Administration
Instruct the patient or caregiver to only use the calibrated dosing spoon supplied with PHEBURANE to measure the oral pellets. Inform the patient or caregiver that the dosing spoon is directly calibrated in grams of sodium phenylbutyrate. Inform the patient or caregiver to consume the pellets immediately after preparation [see Dosage and Administration (2.4)].
Inform the patient or caregiver that if a dose is missed, take the missed dose as soon as possible. Instruct the patient or caregiver that there should be at least 3 hours between two doses and doses should not be doubled to make up for the missed dose [see Dosage and Administration (2.1)].
Storage and Handling
Advise the patient or caregiver to discard any remaining PHEBURANE 45 days after first opening of the bottle.
Distributed by:
Medunik USA, Inc.
2 Research Way, Suite 1B
Princeton, NJ 08540
PHEBURANE® is a registered trademark of Lucane Pharma
Patient Information PHEBURANE (FE bue rayne) (sodium phenylbutyrate) oral pellets |
|
What is PHEBURANE?
|
|
Before taking PHEBURANE, tell your or your child’s healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with PHEBURANE. Especially tell your healthcare provider if you or your child take:
Know the medicines you take. Keep a list of them to show your or your child’s healthcare provider and pharmacist when you get a new medicine. |
|
How should I take PHEBURANE? Read the detailed Instructions for Use that comes with PHEBURANE for information about the right way to prepare and take a dose of PHEBURANE.
|
|
What are the possible side effects of PHEBURANE? PHEBURANE can cause serious side effects, including: Nervous system problems (neurotoxicity). Call your healthcare provider right away if get any of the following symptoms during treatment with PHEBURANE: |
|
|
|
Low potassium levels in your blood (hypokalemia). Your healthcare provider will monitor your blood potassium levels during treatment with PHEBURANE and treat if needed. Conditions related to swelling (edema). PHEBURANE contains salt (sodium), which can cause swelling from salt and water retention. Your healthcare provider will decide if PHEBURANE is right for you if you have certain medical conditions that can cause swelling, such as heart failure, liver problems or kidney problems. The most common side effects of PHEBURANE include: |
|
|
|
Your healthcare provider may do certain blood tests to check you or your child for side effects during treatment with PHEBURANE. These are not all of the possible side effects of PHEBURANE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
|
How should I store PHEBURANE?
Keep PHEBURANE and all medicines out of the reach of children. |
|
General information about the safe and effective use of PHEBURANE. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PHEBURANE for a condition for which it was not prescribed. Do not give PHEBURANE to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about PHEBURANE that is written for health professionals. |
|
What are the ingredients in PHEBURANE? Active ingredient: sodium phenylbutyrate Inactive Ingredients: ethylcellulose, hypromellose, polyethylene glycol 1500, povidone K25, and sugar spheres. Distributed by: Medunik USA, Inc., 2 Research Way, Suite 1B, Princeton, NJ 08540 For more information, go to www.medunikusa.com |
This Patient Information has been approved by the U.S. Food and Drug Administration. |
Issued: August 2023 |
INSTRUCTIONS FOR USE |
Read this Instructions for Use before taking PHEBURANE oral pellets and each time you get a refill. There may be new information. This Instructions for Use does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider or pharmacist if you have any questions about how to take a dose of PHEBURANE.
This Instructions for Use contains information on how to measure and take PHEBURANE.
|
Figure A: Calibrated dosing spoon provided |
Important information you need to know before taking PHEBURANE
Supplies needed for measuring and taking PHEBURANE
Measuring PHEBURANE
Repeat Steps 1 through 3 throughout the day as prescribed by your healthcare provider to get the total daily dose.
Step 1
The calibrated dosing spoon measures PHEBURANE oral pellets as grams (g) of sodium phenylbutyrate. The calibrated dosing spoon dispenses up to 3 g of sodium phenylbutyrate, in increments of 0.25 g.
|
Figure B: Pour the PHEBURANE oral |
Taking PHEBURANE
Step 2
Step 3
or
Do not chew PHEBURANE oral pellets directly or mix PHEBURANE oral pellets into liquids.
If the prescribed divided dose is more than 3 grams, repeat Steps 1 through 3 to get the prescribed divided dose of sodium phenylbutyrate.
Storing PHEBURANE
Disposing of PHEBURANE
If cleaning is necessary, rinse the calibrated dosing spoon with water and dry it completely.
To replace the calibrated dosing spoon, contact Medunik USA at 1-844-884-5520.
Distributed by: Medunik USA, Inc. 2 Research Way, Suite 1B, Princeton, NJ 08540
PHEBURANE® is a registered trademark of Lucane Pharma.
This Instructions for Use has been approved by the U.S. Food and Drug Administration. |
Issued: August 2023 |
NDC: 71770-200-10
Pheburane®
(sodium phenylbutyrate)
oral pellets
84 g per bottle*
Rx only
Pharmacist: Dispense the enclosed
instructions per use with each prescription
Use only the enclosed measuring spoon
designed for use with this product.
Medunik USA
NDC: 71770-210-10
Pheburane®
(sodium phenylbutyrate)
oral pellets
84 g per bottle*
For oral use only
Rx only
Use only the enclosed
measuring spoon designed for
use with this product.
PHEBURANE
sodium phenylbutyrate pellet |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
PHEBURANE
sodium phenylbutyrate kit |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Labeler - Medunik USA (080318531) |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
PHEBURANE 79117600 4281315 Live/Registered |
LUCANE PHARMA 2012-06-05 |